CLINICAL AFFILIATE OF THE TYPE 1 DIABETES TRIALNET
CLINICAL AFFILIATE OF THE TYPE 1 DIABETES TRIALNET
批准号:
8776544
负责人:
JENNIFER B MARKS
金额:
$61.45万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2019-04-30
关键词:
Adolescent and Young AdultAncillary StudyAutoimmunityC-PeptideCD3 AntigensCell physiologyCellsChildChronicClinicalClinical ResearchClinical TrialsDependenceDevelopmentDiabetes MellitusDiagnosisDiseaseEnrollmentEnvironmentFundingFutureGoalsHyperglycemiaIndividualInsulinInsulin-Dependent Diabetes MellitusInternationalInterventionLifeMeasuresMediatingMolecularNatural HistoryOnset of illnessOralPancreasParticipantPathway interactionsPositioning AttributePreventionPrevention strategyPreventive InterventionProcessResearchResearch PersonnelRiskSiteStructure of beta Cell of isletTestingTimeUnited States National Institutes of Healthautoreactive T cellbasebiobankdesigninsulin secretionisletpreventpublic health relevanceresponsesuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Type 1 diabetes (T1D) occurs in genetically predisposed individuals as a result of the progressive, selective destruction of pancreatic ¿-cells, which is primarily mediated by autoreactive T cells. The disease process results in loss of insulin secretion and life-long insulin-dependence, and unfortunately, most often occurs in children, adolescents, and young adults. Years later, these individuals are at risk of developing chronic complications, which can be severely debilitating and life-threatening. The process of ¿-cell destruction begins long before clinical disease onset and continues after development of hyperglycemia; at the time of diagnosis subjects retain a significant amount of ¿-cell function as measured by C-peptide responses to a mixed meal tolerance test (MMTT). However, ¿-cell function continues to deteriorate after diagnosis with the presumed eventuality of near complete loss of secretion over time. At present there is no treatment that fully interdicts islet autoimmunity. However, clinical trials have shown promising results, demonstrating that it is possible to interfere with islet autoimmunity and preserve C-peptide secretion for at least some time. Diabetes TrialNet is a consortium of international researchers, NIH-funded, investigating interventions for the prevention or delay of type 1 diabetes. As a TrialNet Clinical Center our long-term scientific goals are to contribute to the overarching goals of TrialNet: develop a better
understanding of the natural history and molecular basis of T1D and implement clinical trials evaluating new strategies to prevent this disease. The objective of this proposal, a step in pursuit of these goals, is to remain an active participant in the research network, Type 1 diabetes TrialNet, and in the process of designing and implementing new prevention strategies. Each investigative step taken toward modulating the destructive process that leads to T1D moves us closer to the ultimate goal of prevention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1D
-
批准号:8073929
-
项目类别:
-
资助金额:$68.03万
-
财政年份:2009
-
负责人:JENNIFER B MARKS
-
依托单位:
Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1D
-
批准号:8490603
-
项目类别:
-
资助金额:$50.44万
-
财政年份:2009
-
负责人:JENNIFER B MARKS
-
依托单位:
Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1D
-
批准号:7938585
-
项目类别:
-
资助金额:$62.04万
-
财政年份:2009
-
负责人:JENNIFER B MARKS
-
依托单位:
Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1D
-
批准号:8286332
-
项目类别:
-
资助金额:$68.96万
-
财政年份:2009
-
负责人:JENNIFER B MARKS
-
依托单位:
Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1D
-
批准号:7787269
-
项目类别:
-
资助金额:$52.86万
-
财政年份:2009
-
负责人:JENNIFER B MARKS
-
依托单位:
GLYCEMIC CONTROL/COMPLICATIONS TYPE 2 DM MARKERS/MECHANISMS VASCULAR DISEASE
-
批准号:7203234
-
项目类别:
-
资助金额:$1.91万
-
财政年份:2005
-
负责人:JENNIFER B MARKS
-
依托单位:
METABOLIC ASSESSMENTS IN TYPE I DM TO COMPARE RELIABILITY OF MMTT & IV GLUCAGON
-
批准号:7203275
-
项目类别:
-
资助金额:$0.01万
-
财政年份:2005
-
负责人:JENNIFER B MARKS
-
依托单位:
TYPE 1 DIABETES TRIALNET-NATURAL HISTORY OF THE DEVELOPMENT OF TYPE 1 DIABETES
-
批准号:7203268
-
项目类别:
-
资助金额:$0.07万
-
财政年份:2005
-
负责人:JENNIFER B MARKS
-
依托单位:
Carbohydrate /Fat Intake /Cardiovascular Risk with Insul
-
批准号:6981343
-
项目类别:
-
资助金额:$1.02万
-
财政年份:2004
-
负责人:JENNIFER B MARKS
-
依托单位:
Diabetes Prevention Trial of Type 1 Diabetes
-
批准号:6981342
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2004
-
负责人:JENNIFER B MARKS
-
依托单位:
Diabetes TrialNet
-
批准号:7109332
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2001
-
负责人:JENNIFER B MARKS
-
依托单位:
Diabetes TrialNet
-
批准号:6798759
-
项目类别:
-
资助金额:$26.45万
-
财政年份:2001
-
负责人:JENNIFER B MARKS
-
依托单位:
Diabetes TrialNet
-
批准号:6927229
-
项目类别:
-
资助金额:$38.57万
-
财政年份:2001
-
负责人:JENNIFER B MARKS
-
依托单位:
Diabetes TrialNet
-
批准号:6659838
-
项目类别:
-
资助金额:$25.55万
-
财政年份:2001
-
负责人:JENNIFER B MARKS
-
依托单位:
An Altered Peptide Ligand to Prevent Type 1 Diabetes
-
批准号:6442763
-
项目类别:
-
资助金额:$25.51万
-
财政年份:2001
-
负责人:JENNIFER B MARKS
-
依托单位:
Diabetes TrialNet
-
批准号:7285686
-
项目类别:
-
资助金额:$63.52万
-
财政年份:2001
-
负责人:JENNIFER B MARKS
-
依托单位:
An Altered Peptide Ligand to Prevent Type 1 Diabetes
-
批准号:6524767
-
项目类别:
-
资助金额:$26.32万
-
财政年份:2001
-
负责人:JENNIFER B MARKS
-
依托单位:
海外基金